Endocyte slides on vintafolide NSCLC update

Endocyte Inc. (NASDAQ:ECYT) fell $3.28 (24%) to $10.50 on Friday after announcing that a DSMB said vintafolide monotherapy is unlikely to be superior to docetaxel on the primary progression-free survi...